IMMUNOCORE HLDGS ADS/1 Financial Flexibility Index
IMMUNOCORE HLDGS ADS/1 financial flexibility index. IMMUNOCORE HLDGS ADS/1 (6YG) has a Financial Flexibility Index of 0.02x as of June 2026. Free cash flow of €16.71 Million (operating CF €15.93 Million minus capex €786.00K) represents 0% of total liabilities (€699.62 Million). See cash generation quality of IMMUNOCORE HLDGS ADS/1 to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of IMMUNOCORE HLDGS ADS/1 (2022–2025)
Financial flexibility index of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. Historical Financial Flexibility Index trend for IMMUNOCORE HLDGS ADS/1 across 4 annual periods. Check IMMUNOCORE HLDGS ADS/1 (6YG) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
IMMUNOCORE HLDGS ADS/1 Financial Flexibility Index by Year (2022–2025)
IMMUNOCORE HLDGS ADS/1 financial flexibility index by year from 2022 to 2025. Year-by-year free cash flow to debt coverage for IMMUNOCORE HLDGS ADS/1. For the full cash flow conversion analysis, see IMMUNOCORE HLDGS ADS/1 cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.01x | €-6.37 Million | €-10.71 Million | €686.24 Million | ▼ -119.3% |
| 2024 | 0.05x | €31.23 Million | €26.06 Million | €648.79 Million | ▲ +31.3% |
| 2023 | 0.04x | €8.37 Million | €2.94 Million | €228.16 Million | ▲ +114.7% |
| 2022 | -0.25x | €-47.01 Million | €-49.21 Million | €187.86 Million | — |